Serplulimab Combined With CCRT for LS-SCLC.

Status Not yet recruiting

Clinical Trial Summary

Small cell lung cancer(SCLC) has a poor prognosis and a relatively short overall survival time, urgently requiring innovative treatment strategies to improve the prognosis of such patients. Immunotherapy has become an important component of first-line therapy for extensive-stage small cell lung cancer (ES-SCLC). Studies have found that, compared to chemotherapy alone, the combination of Surlidumab with carboplatin and etoposide can extend the median overall survival in ES-SCLC to over 15 months. However, to date, research on the use of immunotherapy in combination with concurrent chemoradiotherapy (CCRT) in limited-stage small cell lung cancer (LS-SCLC) remains limited. This study aims to explore the clinical benefits of Surlidumab in combination with concurrent chemoradiotherapy in LS-SCLC and evaluate the safety of immunotherapy in combination with CCRT as first-line treatment for LS-SCLC. At the same time, it seeks to identify tumor-related biomarkers that can effectively predict the efficacy of immunotherapy and prognosis.

Clinical Trial Description

The study plans to include a total of 96 patients who will receive first-line treatment consisting of 4 cycles of etoposide plus cisplatin/carboplatin and concurrent thoracic radiotherapy combined with Surlidumab immunotherapy. Following CCRT+Surlidumab treatment, patients will undergo Surlidumab consolidation therapy until disease progression or for a duration of at least 1 year. The study aims to evaluate the progression-free survival (PFS) and overall survival (OS) of patients compared to those receiving concurrent chemoradiotherapy alone, and to explore the efficacy of immunotherapy in limited-stage small cell lung cancer. Additionally, peripheral blood samples will be collected before treatment and 1 month after CCRT to explore tumor efficacy-related biomarkers. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06295926
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	mengzhao Wang, MD
Phone	+861311235467
Email	mengzhaowang@sina.com
Status	Not yet recruiting
Phase	Phase 2
Start date	February 25, 2024
Completion date	December 31, 2027

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03651219` - Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT03958045` - Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma	Phase 2
Completed	`NCT04381910` - Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04885998` - AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)	Phase 1
Active, not recruiting	`NCT03703297` - Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy	Phase 3
Recruiting	`NCT05903092` - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer	Phase 2
Completed	`NCT03652077` - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies	Phase 1
Terminated	`NCT04422210` - A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).	Phase 1
Not yet recruiting	`NCT02875457` - Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin	Phase 3
Recruiting	`NCT02577627` - Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC	N/A
Recruiting	`NCT02605811` - Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer	Phase 2
Withdrawn	`NCT02542137` - Abscopal Effect for Metastatic Small Cell Lung Cancer	Phase 2
Completed	`NCT02551432` - Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer	Phase 2
Recruiting	`NCT02262897` - The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer	Phase 2
Completed	`NCT01943578` - Value of Physical Capacity Tests in Lung Cancer	N/A
Terminated	`NCT00969306` - Chloroquine as an Anti-Autophagy Drug in Stage IV Small Cell Lung Cancer (SCLC) Patients	Phase 1
Completed	`NCT01831089` - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors	Phase 1
Completed	`NCT01497873` - A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer	Phase 2
Completed	`NCT00930891` - Bevacizumab in Extensive Small Cell Lung Cancer	Phase 2/Phase 3
Terminated	`NCT00958022` - Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer	Phase 1